753 related articles for article (PubMed ID: 16421514)
1. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
[TBL] [Abstract][Full Text] [Related]
3. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
4. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
Assié MB; Ravailhe V; Faucillon V; Newman-Tancredi A
J Pharmacol Exp Ther; 2005 Oct; 315(1):265-72. PubMed ID: 15987834
[TBL] [Abstract][Full Text] [Related]
5. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Bruins Slot LA; Kleven MS; Newman-Tancredi A
Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
[TBL] [Abstract][Full Text] [Related]
6. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
Depoortere R; Boulay D; Perrault G; Bergis O; Decobert M; Françon D; Jung M; Simiand J; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Nov; 28(11):1889-902. PubMed ID: 12902993
[TBL] [Abstract][Full Text] [Related]
7. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
[TBL] [Abstract][Full Text] [Related]
8. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.
Auclair AL; Galinier A; Besnard J; Newman-Tancredi A; Depoortère R
Psychopharmacology (Berl); 2007 Jul; 193(1):45-54. PubMed ID: 17393144
[TBL] [Abstract][Full Text] [Related]
9. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
10. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
[TBL] [Abstract][Full Text] [Related]
11. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
[TBL] [Abstract][Full Text] [Related]
12. F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release.
Assié MB; Mnie-Filali O; Ravailhe V; Benas C; Marien M; Bétry C; Zimmer L; Haddjeri N; Newman-Tancredi A
Eur J Pharmacol; 2009 Apr; 607(1-3):74-83. PubMed ID: 19326477
[TBL] [Abstract][Full Text] [Related]
13. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
Newman-Tancredi A; Assié MB; Leduc N; Ormière AM; Danty N; Cosi C
Int J Neuropsychopharmacol; 2005 Sep; 8(3):341-56. PubMed ID: 15707540
[TBL] [Abstract][Full Text] [Related]
14. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors.
Gogos A; Kwek P; Chavez C; van den Buuse M
J Pharmacol Exp Ther; 2010 Apr; 333(1):218-27. PubMed ID: 20042529
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
Heusler P; Newman-Tancredi A; Loock T; Cussac D
Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
[TBL] [Abstract][Full Text] [Related]
16. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Assié MB; Carilla-Durand E; Bardin L; Maraval M; Aliaga M; Malfètes N; Barbara M; Newman-Tancredi A
Eur J Pharmacol; 2008 Sep; 592(1-3):160-6. PubMed ID: 18640111
[TBL] [Abstract][Full Text] [Related]
17. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
Boulay D; Depoortère R; Louis C; Perrault G; Griebel G; Soubrié P
Neuropharmacology; 2004 Jun; 46(8):1121-9. PubMed ID: 15111019
[TBL] [Abstract][Full Text] [Related]
18. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.
Zhang M; Ballard ME; Unger LV; Haupt A; Gross G; Decker MW; Drescher KU; Rueter LE
Behav Brain Res; 2007 Aug; 182(1):1-11. PubMed ID: 17570538
[TBL] [Abstract][Full Text] [Related]
19. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
[TBL] [Abstract][Full Text] [Related]
20. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
Claustre Y; Peretti DD; Brun P; Gueudet C; Allouard N; Alonso R; Lourdelet J; Oblin A; Damoiseau G; Françon D; Suaud-Chagny MF; Steinberg R; Sevrin M; Schoemaker H; George P; Soubrié P; Scatton B
Neuropsychopharmacology; 2003 Dec; 28(12):2064-76. PubMed ID: 12902994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
